TL;DR
It is shown that a blood-based circular RNA signature can accurately detect Alzheimer’s disease as well as, or better than, current biomarkers and even predict who will develop symptoms before they appear.
Digital cognitive assessments that target Alzheimer’s-disease-vulnerable systems can detect earlier functional change and strengthen plasma-biomarker prognosis.
BBMs play a crucial role in combating Alzheimer’s disease and should be prioritized, it is essential for governments and health organizations to finance evaluations in varied demographics, establish coverage policies, and integrate BBMs into existing workflows.
Blood‐based biomarkers are essential for early detection, monitoring, and therapeutic development in Alzheimer's disease (AD) and related dementia (ADRD), but current assays lack brain cell specificity and sensitivity to low‐abundant proteins.
This work aimed to evaluate the association between U‐p53AZ with established cerebrospinal fluid (CSF) and neuroimaging measures, and to determine its diagnostic performance in distinguishing cognitively normal individuals from those with mild cognitive impairment (MCI).
Participants with healthier patterns of brain blood flow and oxygen regulation had lower amyloid burden, reinforcing the idea that vascular function may be linked to Alzheimer's-related changes.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
